Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

Quick Access

Favorites
Most Used

All Specialties

OpiCalc Logo
Clinical CalculatorsDrugsGuidelines
SpecsDrugsGuides
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

Registry Hub
Peer-Reviewed Evidence
HomeDrug RegistryCompareAMCILL vs OFIRMEV
Comparative Pharmacology

AMCILL vs OFIRMEV Comparison

Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.

Clinical EssentialsPharmacokineticsSpecial PopulationsSafety & MonitoringPregnancy & LactationClinical Insights
Differential Analysis

AMCILL vs OFIRMEV

Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.

View AMCILL Monograph View OFIRMEV Monograph
AMCILL
Penicillin Antibiotic
Category C
OFIRMEV
Non-opioid Analgesic
Category C
TL;DR — Key Differences
  • Drug class: AMCILL is a Penicillin Antibiotic; OFIRMEV is a Non-opioid Analgesic.
  • Half-life: AMCILL has a half-life of 1-1.5 hours in normal renal function; prolonged to 7-10 hours in anuria.; OFIRMEV has Terminal elimination half-life is 2-3 hours in adults (2.5-3 hours in children). Clinically, dosing every 4-6 hours is needed to maintain therapeutic levels..
  • No direct drug-drug interaction has been documented between AMCILL and OFIRMEV.
  • Pregnancy: AMCILL is rated Category C; OFIRMEV is rated Category C.

Last clinically reviewed: July 2026 · OpiCalc Medical Review Team

Clinical Essentials

AMCILL
OFIRMEV
Mechanism of Action
AMCILL

Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.

OFIRMEV

OFIRMEV (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism of action is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) enzymes in the central nervous system, with minimal peripheral COX inhibition. It may also act on serotonergic pathways and cannabinoid receptors.

Indications
AMCILL

Infections of the respiratory tract,Infections of the genitourinary tract,Meningitis,Septicemia,Endocarditis,Gastrointestinal infections,Prophylaxis of bacterial endocarditis

OFIRMEV

Management of mild to moderate pain,Management of moderate to severe pain with adjunctive opioid analgesics,Reduction of fever

Standard Dosing
AMCILL

250-500 mg orally every 8 hours or 500 mg every 12 hours; for severe infections, up to 1 g every 6 hours intravenously.

OFIRMEV

IV: 1000 mg every 6 hours or 650 mg every 4 hours; maximum single dose: 1000 mg; minimum dosing interval: 4 hours; maximum daily dose: 4000 mg.

Direct Interaction
AMCILL
No Direct Interaction
OFIRMEV
No Direct Interaction

Pharmacokinetics

AMCILL
OFIRMEV
Half-Life
AMCILL

1-1.5 hours in normal renal function; prolonged to 7-10 hours in anuria.

OFIRMEV

Terminal elimination half-life is 2-3 hours in adults (2.5-3 hours in children). Clinically, dosing every 4-6 hours is needed to maintain therapeutic levels.

Metabolism
AMCILL

Partially metabolized by hydrolysis; primarily excreted unchanged in urine via renal tubular secretion and glomerular filtration.

OFIRMEV

Acetaminophen is primarily metabolized in the liver via conjugation with glucuronide (50-60%) and sulfate (20-30%). A minor amount is oxidized by cytochrome P450 (CYP2E1, CYP1A2, CYP3A4) to a toxic reactive metabolite (NAPQI), which is normally detoxified by glutathione. At toxic doses, glutathione is depleted, leading to NAPQI accumulation and hepatotoxicity.

Excretion
AMCILL

Renal: 60-80% unchanged; biliary: less than 10%; fecal: small amount.

OFIRMEV

Primarily renal (85% as sulfate and glucuronide conjugates, 10% as unchanged drug). Less than 5% fecal/biliary.

Protein Binding
AMCILL

20% bound, primarily to albumin.

OFIRMEV

10-25% bound to albumin at therapeutic concentrations.

VD (L/kg)
AMCILL

0.3 L/kg; indicates distribution into extracellular fluid.

OFIRMEV

0.8-1.0 L/kg. Indicates distribution into total body water.

Bioavailability
AMCILL

Oral: 50-70% (variable, reduced by food); IM: nearly 100%.

OFIRMEV

100% (intravenous); not applicable for other routes as OFIRMEV is IV only.

Special Populations

AMCILL
OFIRMEV
Renal Adjustments
AMCILL

For Cr Cl 30-50 m L/min: administer every 12 hours; for Cr Cl 10-29 m L/min: administer every 18-24 hours; for Cr Cl <10 m L/min: administer every 24 hours.

OFIRMEV

No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, extend dosing interval to every 8 hours; maximum daily dose 3000 mg.

Hepatic Adjustments
AMCILL

No specific adjustments recommended for Child-Pugh A or B; use caution in severe hepatic impairment (Child-Pugh C) with monitoring.

OFIRMEV

Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce total daily dose by 50% (max 2000 mg/day). Child-Pugh Class C: Contraindicated or use with extreme caution; reduce dose to 50% of standard and extend interval to every 8 hours; maximum 2000 mg/day.

Pediatric Dosing
AMCILL

Children >1 month: 25-50 mg/kg/day orally divided every 8 hours; for severe infections, up to 100 mg/kg/day IV divided every 6 hours. Maximum dose: 2 g/day.

OFIRMEV

Weight-based: <10 kg: 7.5 mg/kg/dose every 6 hours; 10-50 kg: 15 mg/kg/dose every 6 hours; >50 kg: 1000 mg every 6 hours or 650 mg every 4 hours. Maximum single dose: 15 mg/kg (up to 1000 mg); maximum daily dose: 75 mg/kg (up to 4000 mg).

Geriatric Dosing
AMCILL

No specific dose adjustment required; monitor renal function and adjust based on creatinine clearance.

OFIRMEV

No specific dose adjustment; consider reduced renal function. For Cr Cl <30 m L/min, extend interval to every 8 hours. Maximum daily dose: 3000 mg in frail elderly or with comorbidities.

Safety & Monitoring

AMCILL
OFIRMEV
Black Box Warnings
AMCILL
FDA Black Box Warning

No FDA black box warning.

OFIRMEV
FDA Black Box Warning

Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 mg per day, and often involve more than one acetaminophen-containing product.

Warnings/Precautions
AMCILL

Hypersensitivity reactions including anaphylaxis,Clostridioides difficile-associated diarrhea,Superinfection,Risk of seizures with high doses or renal impairment,Use caution in patients with mononucleosis (high risk of rash)

OFIRMEV

Risk of serious hepatotoxicity, especially with doses >4000 mg/day or in patients with underlying liver disease,Risk of severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis) – discontinue at first sign of rash,Risk of hypersensitivity reactions including anaphylaxis,Use caution in patients with severe hepatic impairment, active hepatic disease, or alcoholism,Avoid concurrent use of other acetaminophen-containing products

Contraindications
AMCILL

Hypersensitivity to ampicillin, penicillins, or any component of the formulation,Infections caused by beta-lactamase-producing organisms

OFIRMEV

Known hypersensitivity to acetaminophen or any component of the formulation,Severe hepatic impairment or active liver disease (relative contraindication without black box)

Adverse Reactions
AMCILL
Data Pending
OFIRMEV
Data Pending
Food Interactions
AMCILL

Food does not significantly affect absorption; may be taken with or without meals. Avoid alcohol: may increase risk of disulfiram-like reaction (rare).

OFIRMEV

No known food interactions. However, avoid excessive alcohol consumption as it may increase the risk of liver damage.

Pregnancy & Lactation

AMCILL
OFIRMEV
Teratogenic Risk
AMCILL

FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. First trimester: Not associated with major birth defects. Second and third trimesters: Use only if clearly needed; potential for altered gut flora and diarrhea in neonate.

OFIRMEV

Acetaminophen (OFIRMEV) is generally considered low risk across all trimesters. No increased risk of major congenital anomalies has been consistently demonstrated. Chronic high-dose use in third trimester may be associated with preterm birth or low birth weight. Avoid prolonged use above recommended doses.

Lactation Summary
AMCILL

Ampicillin is excreted in breast milk in low concentrations (M/P ratio approximately 0.2). Compatible with breastfeeding; monitor infant for diarrhea or rash.

OFIRMEV

Acetaminophen is excreted in breast milk in low concentrations (M/P ratio approximately 0.9-1.0). Considered compatible with breastfeeding; peak milk levels occur 1-2 hours after maternal dosing. Use lowest effective dose for shortest duration.

Pregnancy Dosing
AMCILL

Increased renal clearance during pregnancy may require higher doses to maintain therapeutic levels. Standard dosing is usually adequate for most indications; consider monitoring serum levels in severe infections.

OFIRMEV

No dose adjustment required during pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, clearance) may lead to lower peak concentrations but standard dosing remains effective. Maximum single dose: 1 g; maximum daily dose: 4 g.

Maternal Safety Status
AMCILL
Category C
OFIRMEV
Category C

Clinical Insights

AMCILL
OFIRMEV
Clinical Pearls
AMCILL

AMCILL (ampicillin) is a broad-spectrum penicillinase-sensitive penicillin. Use caution in patients with renal impairment; dose adjustment required for Cr Cl <30 m L/min. Monitor for hypersensitivity reactions, especially in patients with cephalosporin allergy. IV administration may cause phlebitis; rotate infusion sites. Not effective against penicillinase-producing organisms including Staphylococcus aureus.

OFIRMEV

OFIRMEV (acetaminophen) injection is an IV formulation of acetaminophen used for pain and fever management. It is a prodrug that requires no hepatic conversion, providing rapid onset of action. Monitor for hepatotoxicity; maximum daily dose is 4 grams in adults but lower in patients with hepatic impairment or malnutrition. Do not exceed 1 gram per dose. Hypotension and anaphylaxis have been reported. Not interchangeable with oral acetaminophen due to dose equivalency. Use with caution in patients with alcohol use disorder.

Patient Counseling
AMCILL

Take exactly as prescribed; complete full course even if you feel better.,Notify your doctor if you develop rash, hives, or difficulty breathing.,May cause diarrhea; contact your doctor if severe or bloody.,Take with a full glass of water; avoid acidic beverages like orange juice.,Inform your doctor if you are pregnant, breastfeeding, or taking oral contraceptives (ampicillin may reduce efficacy).

OFIRMEV

OFIRMEV is given intravenously for pain or fever.,Do not take additional acetaminophen-containing medications while receiving OFIRMEV.,Report any signs of allergic reaction (rash, itching, swelling, trouble breathing).,Seek immediate medical attention if you experience severe abdominal pain, yellowing of skin or eyes, or dark urine.,Inform your healthcare provider about all medications you are taking, especially blood thinners.

Safety Verification

Known Interactions

AMCILL Risks

No interactions on record

OFIRMEV Risks

No interactions on record

Compare Alternatives

Related Drug Comparisons

Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.

AMCILL vs AMOXICILLINPenicillin Antibiotic
OFIRMEV vs AMOXICILLINPenicillin Antibiotic
AMCILL vs AMOXICILLIN AND CLAVULANATE POTASSIUMPenicillin Antibiotic
OFIRMEV vs AMOXICILLIN AND CLAVULANATE POTASSIUMPenicillin Antibiotic
AMCILL vs AMOXICILLIN PEDIATRICPenicillin Antibiotic
OFIRMEV vs AMOXICILLIN PEDIATRICPenicillin Antibiotic
AMCILL vs Amoxicillin-ClavulanatePenicillin Antibiotic + Beta-Lactamase Inhibitor
OFIRMEV vs Amoxicillin-ClavulanatePenicillin Antibiotic + Beta-Lactamase Inhibitor
AMCILL vs AMOXILPenicillin Antibiotic
Clinical Q&A

Frequently Asked Questions

Common clinical questions about AMCILL vs OFIRMEV, answered by our medical review team.

1. What is the main difference between AMCILL and OFIRMEV?

AMCILL is a Penicillin Antibiotic that works by Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.. OFIRMEV is a Non-opioid Analgesic that works by OFIRMEV (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism of action is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) enzymes in the central nervous system, with minimal peripheral COX inhibition. It may also act on serotonergic pathways and cannabinoid receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.

2. Which is stronger: AMCILL or OFIRMEV?

Potency comparisons between AMCILL and OFIRMEV depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.

3. What is the standard dosing for AMCILL vs OFIRMEV?

The standard adult dose of AMCILL is: 250-500 mg orally every 8 hours or 500 mg every 12 hours; for severe infections, up to 1 g every 6 hours intravenously.. The standard adult dose of OFIRMEV is: IV: 1000 mg every 6 hours or 650 mg every 4 hours; maximum single dose: 1000 mg; minimum dosing interval: 4 hours; maximum daily dose: 4000 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.

4. Can you take AMCILL and OFIRMEV together?

No direct drug-drug interaction has been formally documented between AMCILL and OFIRMEV in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.

5. Are AMCILL and OFIRMEV safe during pregnancy?

The maternal-fetal safety profiles differ. AMCILL is classified as Category C. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. First trimester: Not associated with major birth defects. Second and third trimesters: Use only if clearl. OFIRMEV is classified as Category C. Acetaminophen (OFIRMEV) is generally considered low risk across all trimesters. No increased risk of major congenital anomalies has been consistently demonstrated. Chronic high-dos. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.